Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesInfectious DiseaseAetna HIV resistance testing Coverage Update | Ope…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0316

    HIV Drug Susceptibility and Resistance Tests

    Customize your policy alerts

    Sign up for Aetna Policy 0316 alerts

    Get alerted when Policy 0316 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, investigational indications, and coding guidance for HIV phenotypic and genotypic drug resistance and tropism testing for Aetna members.

    Policy Summary
    PayerAetna
    PolicyHIV Drug Susceptibility and Resistance Tests
    Policy CodePolicy 0316
    Change TypeNo material change
    Effective DateJan 22, 1999
    Last ReviewApr 28, 2023
    Next Review DateMar 14, 2024
    Key ActionOrder resistance or tropism testing only when documentation supports a listed medical necessity indication (e.g., acute infection, suboptimal suppression, or virologic failure) and for tropism testing ensure viral load ≥ 1,000 copies/ml.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3medically necessary groups
    1,000

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    min viral load for tropism
    11RCTs identified
    81400-81408, 87900-87906, 0219UCPT/HCPCS referenced

    Coverage Criteria for HIV Drug Resistance and Tropism Testing

    inv-01: Medically Necessary Indications — Covered when ANY of the following are met

    Covered when ANY of the following are met:

    Medical necessity groups: 1) During acute (new onset) HIV infection to determine if a drug-resistant viral strain was transmitted and plan regimen accordingly; 2) Members with suboptimal suppression of viral load after initiation of antiretroviral therapy to determine the role of resistance and maximize the number of active drugs in the new regimen if indicated; 3) Members with virologic failure during highly active antiretroviral therapy (HAART) to determine the role of resistance in drug failure and maximize the number of active drugs in the new regimen if indicated.

    Supportive documentation should demonstrate the indicated clinical scenario.

    inv-02: Concurrent Testing Policy — Covered with restrictions / Not routinely covered

    Covered with restrictions / Not routinely covered:

    Concurrent phenotypic and genotypic testing: Performing both phenotypic and genotypic resistance tests at the same time is considered not medically necessary because it is duplicative.

    An alternate type of resistance assay (phenotypic or genotypic) may be authorized on an exception basis for members with virologic failure despite adequate therapy when other causes have been excluded and one assay shows no resistance.

    inv-03: Evidence and assay performance — Evidence summary and performance characteristics for resistance testing and Sentosa SQ NGS

    Evidence summary and performance characteristics for resistance testing and Sentosa SQ NGS:

    Evidence summaries: Resistance testing probably improved virological outcomes in people with virological failure in older trials; no evidence of benefit in treatment‑naive patients for mortality or progression to AIDS. NGS has greater sensitivity than Sanger sequencing and detects low‑frequency drug resistance mutations of uncertain clinical relevance.

    Based on Cochrane review and multiple studies cited.

    Sentosa SQ performance findings: Evaluations of the Sentosa SQ HIV‑1 genotyping assay reported high concordance with Sanger sequencing for predicted resistance in many samples (e.g., 80.5% identical interpretation reports in one study; similar predicted resistance in cohorts), detection of additional low‑frequency mutations by NGS, but also substantial technical and QC issues (e.g., 44% of Sentosa runs failed QC in one study) and need for further optimization. Sentosa reliably amplified PR/RT/IN in selected circumstances (e.g., high DNA load), with variable success rates across studies.

    See individual study findings for concordance, additional mutations detected by NGS, QC failure rates, and amplification success thresholds.

    Drug resistance testing is not covered for members who have discontinued antiretroviral therapy because resistance mutations may revert to low-level or minor species that current assays may not detect. Testing is also considered experimental/investigational and may be denied for members with an HIV viral load of <1,000 copies/ml, as available assays cannot reliably detect resistance at that low level. In addition, resistance and susceptibility testing is excluded for indications not explicitly listed as medically necessary, for tropism testing for indications not listed (including repeat tropism testing during or after CCR5 antagonist therapy), and for use of the Sentosa SQ HIV-1 genotyping assay for phenotype prediction.

    A cited systematic review reported no evidence of important patient benefits from resistance testing among treatment‑naive people: resistance testing did not demonstrate important benefits in terms of risk of death or progression to AIDS in treatment‑naive individuals.

    Performing both phenotypic and genotypic resistance tests simultaneously is considered not medically necessary as duplicative. An exception may be considered when virologic failure persists despite one assay showing no resistance, but routine concurrent ordering of both assay types is not supported.

    In randomized trials included in the cited review, resistance testing in treatment‑naive individuals did not show important patient‑level benefits: there was no demonstrated reduction in mortality or progression to AIDS attributable to resistance testing in this population.

    Coding and Testing Thresholds

    Covered CPT/HCPCS when selection criteria are metCPT/HCPCSCovered
    81400-81408Molecular pathology
    87900Infectious agent drug susceptibility phenotype prediction using regularly updated genotypic bioinformatics
    87901Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV 1, reverse transcriptase and protease
    87903Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; first through 10 drugs tested
    87904Each additional drug tested (List separately in addition to code for primary procedure)
    87906Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, other region(e.g. integrase, fusion)
    0219UInfectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis (ie, protease [PR], reverse transcriptase [RT], integrase [INT]), algorithm reported as prediction of antiviral drug susceptibility
    CPT codes not covered for indications listed in the CPBCPTNot Covered
    0219UInfectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis (ie, protease [PR], reverse transcriptase [RT], integrase [INT]), algorithm reported as prediction of antiviral drug susceptibility
    ICD-10 codes referencedICD-10
    B20Human immunodeficiency virus [HIV] disease
    B97.35Human immunodeficiency virus, type 2 [HIV-2], as the cause of diseases classified elsewhere
    Z21Asymptomatic human immunodeficiency virus [HIV] infection status
    inv-11: Viral load threshold for tropism testing
    Viral load threshold>= 1,000 copies/ml
    PurposeMinimum plasma viral load required to reliably determine HIV co-receptor tropism (Trofile) for CCR5 vs CXCR4
    Clinical implicationRequired documentation for tropism testing when considering CCR5 antagonist therapy (eg, maraviroc)

    Provider Requirements, Billing and Operational Notes

    Billing Rule

    Coverage tied to listed codes

    Coverage for the listed CPT/HCPCS and ICD-10 codes is tied to meeting the policy selection and medical necessity criteria. Tests represented by the codes below are covered only when documentation supports one of the medically necessary indications in this policy (acute/new-onset infection, suboptimal suppression after ART initiation, or virologic failure) and when other policy requirements are satisfied.

    • Only the CPT/HCPCS and ICD-10 codes listed in the policy are eligible for coverage when selection criteria are met.
    • Tests billed with codes listed as not covered or experimental (e.g., 0219U) are not eligible except as stated under experimental/investigational exclusions.
    • Ensure coding matches the clinical indication and documentation submitted.
    Note

    Payer policy notice

    This Clinical Policy Bulletin is maintained by Aetna to assist in administering plan benefits. It does not itself guarantee coverage for a specific member — providers should verify member-specific benefits and follow payer-specific requirements for prior authorization and claims submission.

    Background on Resistance Testing

    Phenotypic assays assess in‑vitro drug susceptibility by measuring the drug concentration required to inhibit viral replication, while genotypic assays identify mutations associated with reduced antiretroviral susceptibility. Resistance testing is used to guide selection of active drugs after treatment failure and to detect transmitted resistance in acute infection. Tropism testing (eg, Trofile) determines HIV co‑receptor usage (CCR5 versus CXCR4) to assess suitability for CCR5 antagonists and requires a viral load of >= 1,000 copies/ml for reliable results. Genotypic testing is more widely available and faster; next‑generation sequencing (NGS) methods can detect low‑frequency resistance mutations below Sanger sequencing limits, though the clinical significance of such low‑frequency variants is uncertain.

    Definitions and Test Descriptions

    inv-25: Phenotypic test
    DefinitionAssesses drug susceptibility by measuring the drug concentration that inhibits viral replication in vitro.
    Clinical useUsed to guide selection of active agents for patients with treatment failure and complex prior therapy histories.
    Relation to genotypingProvides complementary information to genotypic assays; no prospective data favoring one assay over the other in all settings.
    inv-26: Genotypic test
    DefinitionIdentifies mutations known to confer reduced susceptibility to antiretroviral drugs.
    Clinical useCommonly used because results are more readily available and returned faster than phenotypic tests.
    Policy Summary
    PayerAetna
    PolicyHIV Drug Susceptibility and Resistance Tests
    Policy CodePolicy 0316
    Change TypeNo material change
    Effective DateJan 22, 1999
    Last ReviewApr 28, 2023
    Next Review DateMar 14, 2024
    Key ActionOrder resistance or tropism testing only when documentation supports a listed medical necessity indication (e.g., acute infection, suboptimal suppression, or virologic failure) and for tropism testing ensure viral load ≥ 1,000 copies/ml.
    SourceLink
    On This Page
    Coverage Criteria for HIV Drug Resistance and Tropism TestingCoding and Testing ThresholdsProvider Requirements, Billing and Operational NotesBackground on Resistance TestingDefinitions and Test Descriptions
    • Policy maintained as a Clinical Policy Bulletin by Aetna.
    • Providers must verify member benefits and eligibility prior to ordering/testing.
    Prior Authorization

    Prior authorization note

    Refer to the main policy document and the member's plan for prior authorization requirements. When prior authorization is required by the member's plan, submit clinical documentation that demonstrates the test meets the medical necessity criteria in this policy.

    • Prior authorization requirements vary by plan — check the member's benefit plan for PA rules and submission instructions.
    • If PA is required, include supporting clinical documentation (see Required clinical documentation callout).
    Denial Risk

    Low viral load

    Testing is considered not medically necessary (and may be denied) for members with an HIV viral load < 1,000 copies/mL because available tests cannot reliably detect resistance or determine tropism at low viral loads.

    • Do not order resistance or tropism testing for members with HIV RNA <1,000 copies/mL unless an exception is documented and justified.
    • Document the viral load value and rationale if requesting testing near this threshold.
    Documentation Required

    Required clinical documentation

    Document clinical indication and relevant clinical data demonstrating that the test is necessary. Required documentation should be submitted with the prior authorization request and with claims when applicable.

    • Clinical indication: acute/new-onset HIV infection, suboptimal suppression after ART initiation, or virologic failure during HAART.
    • Recent plasma HIV-1 RNA (viral load) values with dates (showing viral load >=1,000 copies/mL when applicable).
    • Antiretroviral treatment history, including prior and current regimens and dates of therapy.
    • Evidence of virologic failure or lack of suppression (rising viral load despite adherence and adequate dosing) when applicable.
    • Prior resistance testing results, if available, and rationale for repeat or alternative testing.
    Note

    Supportive references

    Include relevant guideline and evidence references when ordering or interpreting tests; these support clinical justification and may be requested during review.

    • Key supportive references are listed in the policy References section and should be available to support clinical rationale.
    • Studies noting limitations of newer assays (e.g., Sentosa SQ quality control issues) should be considered when interpreting results.
    Note

    Documentation and resources

    Refer to the Clinical Policy Bulletin and linked Aetna resources for plan-specific operational requirements, submission portals, and contact information. The CPB contains additional administrative notes and links to definitions, review history, and glossary resources.

    • Use the CPB Additional Information links for definitions, review history, and plan notices.
    • Verify prior authorization process, submission requirements, and appeal instructions via payer resources.
    Step Therapy

    Step therapy

    No step therapy requirements are specified in this portion of the policy. If a plan imposes step therapy or other utilization management controls, follow plan-specific rules.

    • Policy does not define any step therapy sequences for HIV resistance/tropism testing.
    • Check member’s benefit plan for any step therapy or prerequisite testing requirements.
    RoleRecommended to guide choice of new drugs after treatment failure and considered in acute infection to detect transmitted resistance.
    inv-27: Tropism testing (Trofile)
    DefinitionAssay determining HIV co-receptor usage (CCR5 vs CXCR4) to identify suitability for CCR5 antagonists like maraviroc.
    Viral load requirementRequires plasma viral load >= 1,000 copies/ml for reliable amplification and tropism determination.
    Clinical implicationUsed to identify patients who may benefit from maraviroc; dual/mixed or CXCR4-tropic results contraindicate maraviroc use.
    inv-28: Next-generation sequencing (NGS)
    DefinitionHigh-sensitivity sequencing method that can detect low-frequency HIV drug resistance mutations below the detection limit of Sanger sequencing.
    Clinical noteNGS detects additional low-frequency DRMs of uncertain clinical relevance; larger studies are needed to define their impact.
    PerformanceNGS showed higher sensitivity than Sanger and identified DRMs missed by Sanger in multiple evaluations.
    inv-29: Sentosa SQ HIV-1 Genotyping Assay
    PlatformSentosa SQ HIV-1 Genotyping Assay: a semi-automated Ion Torrent–based NGS platform evaluated for HIV-1 genotypic resistance testing.
    Performance findingsStudies reported high concordance with Sanger for predicted resistance (eg, 80.5% identical interpretation in one study) but also substantial QC/run failures (44% of runs failed QC in another study).
    Operational considerationsQC issues required additional runs and technical refinement; successful sequencing rates varied by region (PRO/RT/INT) and DNA/RNA load.